Abstracts tagged "pregnancy and rheumatoid arthritis (RA)"

Abstract Number: 2411 • 2018 ACR/ARHP Annual Meeting
The Ovarian Reserve Measuring the Anti-Müllerian Hormone Is Not Diminished in Patients with Rheumatoid Arthritis Compared to the Healthy Population
Mireia López-Corbeto¹, Sara Marsal¹, Andrea Pluma², Sergio Martinez², Maria Lopez-Lasanta², Agusti Sellas-Fernandez², Juan José de Agustín² and Mireia Barcelo², ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is the most prevalent chronic inflammatory arthritis, affecting 0.5-1% worldwide population and predominates in females. Altered fertility has been reported due…
Abstract Number: 2425 • 2018 ACR/ARHP Annual Meeting
The Impact of Biologic Treatment for Rheumatoid Arthritis Patients Who Hope to Conceive
Hiromi Shimada, Taichi Miyagi, Mikiya Kato, Risa Wakiya, Shusaku Nakashima, Tomohiro Kameda and Hiroaki Dobashi, Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Previous reports revealed that it was difficult for rheumatoid arthritis (RA) patients to conceive1). Age, nulliparity, disease activity, NSAIDs, corticosteroid was known as the…
Abstract Number: 1031 • 2017 ACR/ARHP Annual Meeting
Developing a Multi-Phase Claims-Based Algorithm to Facilitate the Study of Drug Exposure during Pregnancy
S Phillips¹, KE Johnson¹, SW Shen², KJ Woodcroft³, SA Oliveria⁴ and TA Simon⁵, ¹QuintilesIMS, Seattle, WA, ²Bristol-Myers Squibb, Hopewell, NJ, ³Henry Ford Health System, Detroit, MI, ⁴QuintilesIMS, New York, NY, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The use of antirheumatic medications during pregnancy may lead to birth defects or other complications. Safety studies are critical, with registries being common but…
Abstract Number: 1313 • 2017 ACR/ARHP Annual Meeting
Oral Corticosteroid Use during Pregnancy and Risk of Preterm Birth in Women with Rheumatoid Arthritis
Kristin Palmsten¹, Gretchen Bandoli², Diana L Johnson¹, Ronghui Xu^3,4 and Christina D Chambers¹, ¹Department of Pediatrics, University of California, San Diego, La Jolla, CA, ²Pediatrics, University of California, San Diego, La Jolla, CA, ³Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁴Department of Mathematics, University of California, San Diego, La Jolla, CA
Background/Purpose: There are limited data regarding gestational timing of oral corticosteroid (OCS) use during pregnancy and risk of preterm birth. The objective was to compare…
Abstract Number: 1315 • 2017 ACR/ARHP Annual Meeting
Influence of Rheumatoid Arthritis and Axial Spondyloarthritis on Pregnancy Complications, Pregnancy Outcome and Delivery Mode
Frauke Förger¹, Stephanie van den Brandt², Astrid Zbinden³, Monika Ostensen³ and Peter M. Villiger³, ¹Inselspital, University of Bern, Bern, Switzerland, ²Clinical Immunology and Rheumatology, University of Amsterdam, Amsterdam, Netherlands, ³Rheumatology, Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland
Background/Purpose: To analyze pregnancy complications, pregnancy outcome and delivery mode in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA).Methods: Patients with RA and axSpA…
Abstract Number: 1317 • 2017 ACR/ARHP Annual Meeting
Obstetric Outcomes in Women with Rheumatoid Arthritis: Results from Nationwide Inpatient Sample Database 2003-2011
Shweta Kishore¹, Varun Mittal², Venkataraman Palabindala³, Shradha Ahuja³ and Vikas Majithia^1,4, ¹Division of Rheumatology, University of Mississippi, Jackson, MS, ²Division of Hematology and Oncology, Albert Einstein Healthcare Network, Philadelphia, PA, ³Division of Hospital Medicine, University of Mississippi, Jackson, MS, ⁴Jackson VA Medical Center and University of Mississippi, Jackson, MS
Background/Purpose: Fertility is reduced in patients with Rheumatoid Arthritis (RA) due to unknown cause. Few studies mostly involving single center cohorts have addressed pregnancy outcomes…
Abstract Number: 1785 • 2017 ACR/ARHP Annual Meeting
Serious or Opportunistic Infections in Infants Born to Pregnant Women with Rheumatoid Arthritis and Treated with a Biologic Medication
Christina D Chambers¹, Diana L Johnson², Yunjun Luo³, Ronghui Xu⁴ and Kenneth L Jones³, ¹Pediatrics and Family Medicine and Public Health, University of California San Diego, La Jolla, CA, ²Department of Pediatrics, University of California, San Diego, La Jolla, CA, ³Pediatrics, University of California San Diego, La Jolla, CA, ⁴Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA
Background/Purpose: Use of biologic therapies for rheumatoid arthritis (RA) in pregnancy is common. There is theoretical concern that these medications could interfere with postnatal…
Abstract Number: 2432 • 2017 ACR/ARHP Annual Meeting
Longitudinal Changes in Gene Expression Associated with Disease Activity during Pregnancy and Post-Partum Among Women with Rheumatoid Arthritis
Dana E. Goin^1,2, Mette Smed³, Nicholas Jewell², Lior Pachter^2,4, J. Lee Nelson^5,6, Hanne Kjaergaard³, Jørn Olsen⁷, Merete Lund Hetland^8,9, Bent Ottesen³, Vibeke Zoffmann³ and Damini Jawaheer^1,7,10, ¹UCSF Benioff Children's Hospital Oakland/CHORI, Oakland, CA, ²University of California, Berkeley, Berkeley, CA, ³Juliane Marie Center, Copenhagen, Denmark, ⁴California Institute of Technology, Pasadena, CA, ⁵Fred Hutchinson Cancer Research Center, Seattle, WA, ⁶University of Washington, Seattle, WA, ⁷Aarhus University, Aarhus, Denmark, ⁸The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, ⁹University of Copenhagen, Copenhagen, Denmark, ¹⁰University of California, San Francisco, San Francisco, CA
Background/Purpose: Many women with rheumatoid arthritis (RA) experience an improvement in disease activity during pregnancy, and a predictable flare in the months after they give…
Abstract Number: 2433 • 2017 ACR/ARHP Annual Meeting
Transcriptome Analysis in Women with Rheumatoid Arthritis Who Improve or Worsen during Pregnancy
Dana E. Goin^1,2, Mette Smed³, Lior Pachter^2,4, Elizabeth Purdom², J. Lee Nelson^5,6, Hanne Kjaergaard³, Jørn Olsen⁷, Merete Lund Hetland^8,9, Bent Ottesen³, Vibeke Zoffmann³ and Damini Jawaheer^1,7,10, ¹UCSF Benioff Children's Hospital Oakland/CHORI, Oakland, CA, ²University of California, Berkeley, Berkeley, CA, ³Juliane Marie Center, Copenhagen, Denmark, ⁴California Institute of Technology, Pasadena, CA, ⁵Immunogenetics, Fred Hutchinson Cancer Rsch, Seattle, WA, ⁶University of Washington, Seattle, WA, ⁷Aarhus University, Aarhus, Denmark, ⁸The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, ⁹University of Copenhagen, Copenhagen, Denmark, ¹⁰University of California, San Francisco, San Francisco, CA
Background/Purpose: Gene expression changes induced by pregnancy in women with rheumatoid arthritis (RA) and healthy women have not been examined. The few studies previously conducted…
Abstract Number: 992 • 2016 ACR/ARHP Annual Meeting
The Impact of Inflammatory Arthritis (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, reactive arthritis) on Maternal and Neonatal Outcomes: A Population-Level Analysis
Stephanie Keeling¹, Anamaria Savu² and Padmaja Kaul³, ¹Department of Medicine, Division of Rheumatology, Edmonton, AB, Canada, ²Canadian Vigour Center, Edmonton, AB, Canada, ³Cardiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The impact of inflammatory arthritis (IA) including rheumatoid (RA), psoriatic (PsA), and spondyloarthritis (SpA) on maternal, obstetrical and neonatal outcomes is not well described…
Abstract Number: 1517 • 2016 ACR/ARHP Annual Meeting
Does Inflammatory Arthritis Really Improve during Pregnancy? a Systematic Review and Meta-Analysis
Hannah Jethwa¹, Suzanne Lam², Colette Smith³ and Ian Giles⁴, ¹General Medicine, Wexham Park Hospital, London, United Kingdom, ²Croyden University Hospital, London, United Kingdom, ³Statistics, Royal Free Hospital Foundation Trust, London, United Kingdom, ⁴Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Disease activity is considered to improve in approximately 75% of patients with rheumatoid arthritis (RA) during pregnancy. This figure, however, is derived from…
Abstract Number: 2049 • 2016 ACR/ARHP Annual Meeting
Serious Infections in RA Offspring Exposed to Tumor Necrosis Factor Inhibitors
Evelyne Vinet¹, Cristiano S. Moura², Jeffrey R. Curtis³, Christian A. Pineau⁴, Michal Abrahamowicz² and Sasha Bernatsky⁵, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Center for Education and Research on Therapeutics, University of Alabama at Birmingham, Birmingham, AL, ⁴McGill University Health Centre, Montreal, QC, Canada, ⁵Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are increasingly used during RA pregnancy. Most of these are actively transported across the placenta, reaching higher fetal than maternal…
Abstract Number: 2441 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Flares and Pregnancy Outcomes Among Women in a Longitudinal Registry
Sara K. Tedeschi, Michelle Frits, Christine Iannaccone, Michael Weinblatt, Nancy A. Shadick and Bonnie L. Bermas, Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) has been reported to improve during 50-60% of pregnancies. In this study, we evaluated RA disease activity during pregnancy and pregnancy…
Abstract Number: 2522 • 2015 ACR/ARHP Annual Meeting
High Risk of Flares during Pregnancy in Women with Rheumatoid Arthritis Who Discontinue Treatment with TNF Inhibitors at Conception
Rebecca Fischer-Betz¹, Oliver Sander¹, Christof Specker², Ralph Brinks³ and Matthias Schneider¹, ¹Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ²Rheumatology and clinical immunology, Kliniken Essen Sued, Essen, Germany, ³Hiller Center for Research in Rheumatology, Duesseldorf, Germany
Background/Purpose: Optimal treatment of women with Rheumatoid Arthritis (RA) during pregnancy remains a challenge, mainly due to safety concerns. TNF inhibitors (TNFi) are now routinely…
Abstract Number: 2526 • 2015 ACR/ARHP Annual Meeting
Perinatal Patterns of Medication Use in Women with Rheumatoid Arthritis: A Population-Based Study
Mary A De Vera^1,2, Eric C. Sayre², Nicole Tsao^1,2 and J Antonio Avina-Zubieta^2,3, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Perinatal Patterns of Medication Use in Women with Rheumatoid Arthritis: A Population-based StudyBackground/Purpose: Although the incidence of RA peaks during the 4th and 5th decades…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].